Medincell Temporarily Suspends Trading on Euronext Paris

Medincell has announced a temporary suspension of trading its shares on Euronext Paris. The suspension commenced with the market's opening at 9:00 a.m. (CEST), following the company's request in anticipation of a forthcoming press release.

Medincell, based in Montpellier, France, is an innovation-driven biopharmaceutical company focused on developing long-acting injectable treatments across various therapeutic areas. Its proprietary BEPO® technology supports controlled drug delivery. Medincell collaborates with partners like Teva Pharmaceuticals, which markets Risperidone LAI as UZEDY® in the U.S.

Medincell's development pipeline includes numerous therapeutic candidates progressing through various clinical stages. Its strategic partnerships aim to enhance medicine effectiveness while reducing environmental impact.